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ABSTRACT
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Nalin Gupta M.D.,‡ Kathleen R. Lamborn Ph.D.,‡ Michael D. Prados M.D.,‡ Mitchel S.
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Departments of *Radiation Oncology, †Pediatrics, and ‡Neurological Surgery and Brain
Tumor Research Center, University of California, San Francisco, CA. (Sponsored by
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School of Medicine)
Purpose: We reviewed a historical cohort of pediatric patients with supratentorial
primitive neuroectodermal tumors (sPNET) in order to clarify the role of radiation in the
treatment of these tumors.
Patients and Methods:
Fifteen children <18 years old with non-pineal sPNETs diagnosed between 1992 and
2006 were identified. Initial therapy consisted of surgical resection and chemotherapy
(CT) in all patients and up-front radiotherapy (RT) in 5 patients. Five patients had RT at
the time of progression and five received no RT whatsoever. Kaplan-Meier estimates of
overall-survival (OS) were then calculated.

Results: The median follow-up from diagnosis for all patients was 31 months (range 0.5165) and for surviving patients was 49 months (range 10-165). Of the 5 patients who
received up-front RT, all were alive without evidence of disease at a median follow-up of
50 months (range 25-165). Only 5 of the 10 patients who did not receive up-front RT
were alive at last follow-up. There was a statistically significant difference in overall
survival between the group of patients that received up-front RT and the group that did
not (P=0.048). Additionally, we found a trend toward a statistically significant
improvement in overall-survival for those patients that received gross total resections
(P=0.10).
Conclusions: Up-front radiotherapy and gross total resection may confer a survival
benefit in patients with sPNET. Local failure was the dominant pattern of recurrence.
Efforts should be made to determine patients most likely to have local failure exclusively
or as a first recurrence in order to delay or eliminate cranio-spinal irradiation (CSI).
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INTRODUCTION:
Supratentorial primitive neuroectodermal tumors (sPNET) were first described in
1973 and are defined as poorly differentiated, embryonal, predominantly pediatric tumors
that arise in the cerebrum or suprasellar region, comprising approximately 2-3% of all
childhood brain tumors (1). Since their discovery, the traditional consensus has been that
sPNETs simply represent a slight, although considerably more aggressive, variation on
their infratentorial cousins—medulloblastomas. But it is slowly becoming apparent that
these tumors are very distinctive entities with critical differences as compared to
medulloblastomas. This re-evaluation is largely being driven by studies which seem to
suggest that sPNETs have a unique biology. However, it was the knowledge regarding
their clinical behavior, gained since their discovery, that first hinted at these comparative
biological differences.

Epidemiology and Diagnosis: Compared to medulloblastomas, sPNETs arise
approximately 1/10th as frequently, comprising only 3 to 7% of all primary pediatric CNS
lesions (2). Within the pediatric age group, 80% of these lesions are diagnosed before
age 10, 65% before age, and 25% before age 2 (3). To date, there has been no reported
sex preference in terms of diagnosis. In adults, sPNETs occur even less frequently, ,
although, adult patients appear to have increased survival relative to their pediatric
counterparts (4).
Of interest, there appears to be a subset of pediatric patients who received craniospinal irradiation as part of their treatment for hematological malignancies who later
develop high grade glial tumors, including sPNET, as a consequence of their prior
irradiation (5); such secondary sPNETs can also arise after treatment for other primary
CNS neoplasms, again as a consequence of neuraxis radiation. Some patients in whom
these secondary sPNETs develop have a tumor predisposing genetic condition such as a
Retinoblastoma or Neurofibromatosis. For others, however, there is no obvious genetic
lesion that might help to explain the development of a secondary malignancy in response
to initial therapy for prior disease (6).

The primary distinction between medulloblastomas and sPNET is, of course,
location of occurrence—infratentorially in the former and supratentorially in the latter.
More specifically, sPNETs tend to predominantly occur in the cerebrum or suprasellar
region. Less frequently, sPNETs can originate in the retina, pineal gland, deep
paraventricular region, diencephalon, and basal ganglia. Case reports have also made
mention of sPNET presentation in the leptomeninges without evidence of a primary
cerebral lesion, although this is exceedingly rare (7). Indeed, it may simply represent a
microscopic primary with early dissemination. Metastasis at presentation, however, is
not uncommon in sPNETs, with approximately 13-27% of patients having some degree
of dissemination at diagnosis (8).
sPNET and medulloblastomas share a common staging system, the Chang
Metastasis Staging System. Using this system, an M0 lesion is defined as a primary
lesion without evidence of subarachnoid or hematogenous spread. An M1 lesion is one
where CSF studies reveal tumor cells. M2 disease evidences gross nodular seeding in the
intracranial subarachnoid space or ventricular system distant from the primary site,
whereas M3 disease presents with gross nodular seeding in the spinal subarachnoid
space. Finally, any extra-neural disease is classified as M4 (9).
The presentation of sPNETs can very widely both within and between different
populations. For adults and older children, signs of increased intracranial pressure are
often seen, including headache, nausea, and vomiting. Less frequently, patients may
present with seizures or focal neurological deficits (2). If leptomeningeal dissemination
has already occurred, patients may suffer from cranial nerve palsies, encephalopathy, or
spinal cord symptoms. When compared to older age cohorts, the youngest patients have

a distinctive subset of symptoms with irritability, anorexia, lethargy, or enlarging head
circumference tending to predominate (10).
Initial diagnostic work-up will invariably include both CT and MR imaging. CT
often demonstrates a well-circumscribed, usually hemispheric mass that can contain both
areas of calcification and necrosis. Although less common, CT may also show evidence
of intra-tumoral hemorrhage. MR imaging will show significant heterogeneity, with
hypointense portions representing hemosiderin deposition and calcification. On T1weighted MR imaging, hyper-intense regions represent areas of hemorrhage, while on
T2-weighted scans, these hyperintense foci are often cystic components. Unlike gliomas,
for sPNETs, peri-tumoral edema is relatively absent (11). Overall, while imaging may be
suggestive of diagnosis, more definite conclusions require histological examination.
Unfortunately, definitive diagnosis of sPNETs remains a significant challenge to
clinicians, since they are almost histologically indistinguishable from medulloblastoma.
Current WHO criteria define sPNETs as Grade IV tumors comprised of at least 90%
undifferentiated or poorly differentiated neuroepithelial cells. This differs slightly from
the commonly accepted definition in United States, where any embryonal tumor
composed of small round blues cells located above the tentorium, regardless of location,
presence of focal differentiation, extent of resection, or metastatic stage, is considered a
sPNET (12). Additionally, it is recognized that sPNETs have the ability to differentiate
along multiple pathways, including neuronal, astrocytic, ependymal, muscular, and
melanocytic.
Because of the paucity of histological markers specific for sPNETs, diagnostic
criteria rely almost exclusively on their location and their relative lack of differentiation.

However, even this definition is troublesome for pathologists as it is oftentimes the case
that sPNETs are dedifferentiated to the point where it is difficult to distinguish them from
“round” or “small cell” glioblastoma variants (13). And in very young children, it is
important to decide whether polyphenotypic sPNETs with epithelial membrane antigen
and smooth muscle actin might actually represent CNS rhabdoid tumors.

Biology: But while the diagnostic picture for sPNETs remains muddled, researchers are
increasingly coming to realize that these tumors have a distinctive biology that separates
them from their infratentorial counterparts. Initial karyotypic studies in a series of 22
pediatric sPNETs demonstrated the presence of both double minute structures and a high
level of gene amplification. More surprisingly was the finding that in eight of the 22
cases, the karyotype was normal (3). The remaining 13 cases showed complex
karyotypes involving mostly structural changes, including interstitial deletions, partial
chromosome gains, and chromosomal translocations. The cytogenetic abnormalities that
recurred with the greatest frequency included deletions or translocations in chromosome
10q22-26 (3 of 13 cases) and translocations that involved chromosome 6q21-25 (2 of 13
cases). Interestingly, the tumor in one individual evidenced a translocation involving
chromosome 6q25 and chromosome 13q14. The tumor suppressor RB1 resides on
chromosome 13q14 and this translocation may somehow involve constitutional
inactivation of this gene.
Comparative Genomic Hybridization (CGH) studies completed on approximately
16 sPNET patients revealed a greater frequency of imbalances than was seen on
traditional karyotypic analysis (14,15,16). These data demonstrated that sPNETs have

significant differences in the pattern and frequency of DNA copy number changes as
compared to medulloblastomas. One of the more common genetic abnormalities in
medulloblastomas is chromosome 17 loss. This was not apparent in any of the sPNETs
examined. A characteristic isochromosome 17, resulting from the gain of chromosome
17q and loss of 17p, is seen in approximately 40% of medulloblastomas. For sPNETs,
only one case of isochromosome 17 has been reported. However, more recent work
using CGH arrays and FISH analysis have shown that a fraction of sPNETs do indeed
have abberations on chromosome 17 (17). Additionally, epigenetic modifcations in
breakpoint cluster regions are often seen in medulloblastomas, appearing in
approximately 30% of those examined. Again, these alterations have not been seen in
any of the sPNETs characterized to date (18).
Although specific changes common to medulloblastomas were not seen in
sPNETs, a study of approximately 17 pediatric sPNETs using CGH demonstrated a
higher frequency and greater complexity of DNA copy number changes when compared
to medulloblastomas (19). Approximately 70% of tumors evidenced genomic
imbalances, with a median of four changes per tumor. Of those changes, the majority
involved entire chromosomes, whereas partial chromosomal imbalances were seen in
37% of tumors. In these 17 cases, the vast majority of alterations involved chromosomal
loss rather than gain. The most common loss, seen in approximately 50% of these cases,
was loss of chromosome 4q. Other, less frequently seen, regions of deletions occurred in
distal areas of 9p, 13q, 14q, and 10q. The tumor suppressors that putatively reside in
many of these regions have yet to be characterized, however, losses in regions of
chromosome 10q, which include tumor suppressors such as PTEN and DMBT1, were

seen in approximately 25% of sPNETs examined (20). And although chromosomal gains
were far less frequent in sPNETs, those seen tended to mirror ones already identified in
medulloblastoma. Most notable were gains at chromosome 7 and the q arm of
chromosome 1. Again, less frequently observed are gains on chromosomes 9qter, 13 and
17. More recent work has shown that a gain of chromosome region 20q13.33 is seen in a
not insignificant number of sPNETs. This corresponds to a region frequently amplified
in glioblastoma that results in the constitutive overexpression of the CD95 decoy receptor
(17).
While karyotypic and CGH analyses have tended to support the notion that
sPNETs are neoplasms distinct from medulloblastoma, microarray studies looking at
expression differences have gone a long way towards confirming this idea. One of the
seminal works in support of this notion was published by Pomeroy, et al (21). Having
analyzed approximately 99 patient samples that included sPNETs, medulloblastomas,
atypical teratoid/rhabdoid neoplasms, and malignant gliomas, the authors concluded that
there were distinctive pathways that were differentially expressed in medulloblastomas
compared to sPNETs.

Specifically, the transcription factors ZIC1 and NSCL were

overexpressed in medulloblastomas but not sPNETs. Based on this finding, the authors
argued that these two tumor types might have different cells of origin, with the original
idea being that they both arose from cerebellar granule cells. But the question remains—
what pathways, by way of increased activation, are critical to the development of
sPNETs?
The Shh-Gli pathway is one pathway crucial in normal cerebral development that
may play a role in sPNET tumorigenesis. In murine models, the Gli proteins (Gli1-Gli3),

downstream effectors of Shh, exert strong mitogenic effects on nestin positive neocortical
precursor cells in the subventricular zone (22). Some studies have shown that, in a
significant fraction of sPNETs, Gli1 mRNA is overexpressed (23). Additionally, in a
small series of sPNETs examined by IHC, there appeared to be increased expression of
the n-MYC oncoprotein, itself a known downstream target activated by the Shh signaling
pathway (24). These findings have recently been confirmed by expression microarray
data that found n-MYC overexpression in approximately 30% of sPNETs examined (25).
Finally, missense mutations in the PTCH locus, a gene whose protein product is known to
antagonize Shh signaling, have been identified in 3 in a series of 8 pediatric sPNETs
examined (26).
Another pathway critical in neurogenesis that may play a role in sPNET
development is the Notch-Hes signaling cascade. The Notch proteins, four of them have
been identified, are large, membrane spanning receptors for ligands such as Jagged and
Delta that are themselves membrane bound. Upon ligand binding, the Notch receptor is
cleaved and the intracellular fragment translocates to the nucleus where it serves as a
transcription factor instrumental in the activation of the Hes family proteins (27). Hes
proteins themselves then negatively regulate transcription factors such as hASH1.
Evidence abounds for the involvement of the Notch-Hes pathway in both proliferation
and differentiation. Not surprisingly, aberrant Notch signaling is often seen in neoplastic
lesions. Most notably, in certain variants of T-cell leukemia a translocation results in
constitutive activation of the gene (28). It has been shown that the Notch2 mRNA is
overexpressed in sPNETs compared to medulloblastoma and control cerebellar cells (29).
The overexpression of Notch2 in these tumors appears to result from genomic

amplification of the Notch2 gene locus. Compellingly, knockdown of Notch2 expression
in a sPNET cell line successfully decreased its proliferative capacity.
A final pathway where increased activity may play a role in the development
of sPNETs is the fabled Wnt cascade. Wnt signaling plays a crucial role in many of the
canonical steps in tumorigenesis, including differentiation, proliferation, and invasion.
The cascade is initiated by binding of Wnt to the transmembrane protein Frizzled. This
causes the activation of the Dishevelled family of proteins, ultimately leading to the
cytosolic stabilization, and eventual translocation to the nucleus, of β-Catenin. Once in
the nucleus, β-Catenin serves to transcriptionally activate a variety of oncogenes,
including c-MYC and n-MYC (30). While not conclusive by any means, there is some
suggestion that the Wnt cascade might play a role in a fraction of sPNETs. In a series of
only 4 sPNETs, one tumor evidenced a mutation in β -Catenin that resulted in increased
stabilization and thus nuclear accumulation of the protein (31). The increased stability of
β-Catenin was a result of a mutation in its protein degradation targeting sequence.
Although earlier it was suggested that Shh signaling might be responsible for the
increased expressin of N-myc in sPNETs, it is equally plausible that this type of βCatenin mutation might be responsible for the observed alteration in N-myc protein
levels.
So while activation of the above oncogenic pathways appear to be important in
sPNETs, a further discussion of tumor suppressors that, when inactivated, might play
equally important roles in the development of these lesions, is necessary. Firstly, there is
some evidence to suggest that, at least in the case of adult sPNETs, mutational
inactivation of the classic tumor suppressor, p53, might play an etiologic role. p53 is, of

course, involved in DNA repair, cell cycle arrest, and the induction of apoptosis; it is
often referred to as the “guardian of the genome” (32). In a study involving 11 adult
sPNETs, mutations in p53 were observed in six cases (33). In stark contrast, in the 28
cases of pediatric sPNETs examined, only one was found to have a p53 mutation (34).
Secondly, there is some evidence to suggest that upwards of 20% of sPNETs have
deletions of the tumor suppressor DMBT1 (Deleted in Malignant Brain Tumors-1), a
membrane bound glycoprotein containing multiple scavenger receptor cysteine-rich
(SRCR) domains separated by SRCR-interspersed domains (SID) (35). It is proposed
that DMBT1 plays a role in both immune defense and epithelial differentiation. Thirdly,
there is a case report of a germline mutation in the mismatch-repair gene PMS2 leading
to the development of sPNETs in two consanguineous twins (36). Fourthly, Pfister, et al
have recently discovered, using CGH array technology, that a significant number of
sPNETs (7 of 21 examined) have either heterozygous or homozygous deletion of the
CDKN2A locus. This locus is responsible for the production of two critical cell-cycle
inhibitors, p16INK4A and p14ARF; the former acts by deactivating various cyclin-CDK
complexes, while the latter functions to promote p53 expression by inhibiting MDM2.
And finally, and more surprisingly, is the possible role of the tumor suppressor MSH2 in
sPNET tumorigenesis. MSH2 is frequently mutated in hereditary non-polyposis colon
cancer (HNPCC) and, like PMS2, plays a crucial role in mismatch repair mechanisms.
Deletions of MSH2 result in accelerated tumor formation in knock-out mice. However,
in sPNETs, it appears that MSH2 expression is increased (25). This is consistent with
observations made in glioblastoma and medulloblastoma. At this time, the significance
of this overexpression of a known tumor suppressor in these neoplasms is unclear.

Despite the significant advances in the knowledge of sPNET biology, the
treatments for these tumors largely center on the use of protocols originally designed to
target high-risk medulloblastomas.

Treatment and Prognosis: There are two major challenges that have made the
identification of significant prognostic factors and the optimization of treatment strategies
difficult in cases of sPNET: 1) the relative difficulty in distinguishing these lesions from
the myriad other cerebral neoplasms and 2) their relative paucity. Indeed, in the ongoing
COG trial 99701, several patients enrolled that had thalamic tumors that were originally
thought to be sPNETs, upon surgical biopsy were found to have glioblastoma multiforme.
Because of the difficultly posed in identifying these tumors pathologically, it must be
remembered that any clinical trial involving sPNET patients may have limited
applicability given inter-institutional variation in the peculiarities of diagnosis.
Because they are infrequent, clinical trials devoted exclusively to sPNET are
relatively few in number. One of the earliest randomized controlled trials was the CCG
921 trial (37). This trial involved 55 patients, ages 1.5 to 19.3 years. Patients were
randomized to one of two arms. In the first arm, patients received cranio-spinal
irradiation followed by eight cycles of 1-(2-chloro-ethyl)-3-cyclohexylnitrosourea
(CCNU), vincristine, and prednisone. The second arm involved two cycles of 8-in-1
chemotherapy followed by RT and then eight additional cycles of 8-in-1 chemotherapy.
The 8-in-1 regimen included methyprednisone, vincristine, carmustine, procarbazine,
hydroxyurea, cisplatin, cytarabine, and cyclophosphamide.

For all patients in the study, three year Kaplan-Meier estimates of overall survival
(OS) and progression free survival (PFS) were 57% and 47%, respectively. There was no
statistically significant difference in either OS or PFS between the two treatment arms,
although, not unsurprisingly, the more chemotherapy intensive regimen had greater
toxicity. Univariate analysis revealed that both metastasis at diagnosis and age adversely
affected PFS. For M0 patients, 50% had no progression at 3 years, while all patients that
were M2-M4 had progressed. For patients that were 1.5-2 years of age at diagnosis, 25%
had not progressed by year 3 versus 50% of those that were older than 3.
The next major prospective trials evaluating treatment options for sPNET patients
were the German HIT 88/89 and HIT 91 trials (38). Here 63 pediatric patients (ages 318) were enrolled after surgery, with 21 patients having gross total resections of their
tumors. Patients were then randomized to two different treatment arms—one involved
pre-irradiation chemotherapy with two cycles of ifosfamide, etoposide, methotrexate,
cisplatin, and cytarabine; the second arm involved post-irradiation chemotherapy
consisting of eight cycles of cisplatin, vincristine, and lomustine. It was recommended
that radiation be administered to the entirety of the neuraxis to a dose of 35.2 Gy, with a
boost of 20 Gy to the primary site. Despite these recommendations, seven patients were
treated with 54.0 Gy limited to the site of the primary lesion.
Again, OS was approximately 48% at 3 years. Thirty-eight patients had
progressed, with local failure in 27 of these patients. There was a dramatic difference in
survival between patients that received the recommend dose and volumes of radiotherapy
and those that did not. The PFS for adherent patients was 49.3% at 3 years compared to
6.7% in those patients that received sub-optimal radiotherapy. From this, the authors

concluded that cranio-spinal irradiation (CSI) was necessary to at least 35 Gy with boost
to the primary site of at least 20 Gy.
The first results that arrived from the German trials concerned only children
above age 3. Unfortunately, and especially for those under 3 years of age, there are
significant long-term toxicities, in particular neuropsychological morbidity, associated
with the use of radiotherapy, especially cranio-spinal irradiation (CSI) (39-41).
Concerted recent effort has therefore been devoted to alternative therapeutic regimens
that eliminate radiation, delay radiotherapy, or reduce radiation dosages or fields. It was
with these concerns in mind that Timmermann, et al evaluated the survival data on 29
children ages 3-37 months that had been enrolled in the HIT-SKK87 and HIT-SKK92
trials (42).
In the earlier trial, HIT-SKK87, the children were divided into two arms
depending upon the extent of resection and the presence of metastases. Low risk patients
received maintenance chemotherapy until RT was administered after age 3, while highrisk patients received intensive induction chemotherapy followed by a maintenance
regimen until RT was administered, again after age 3. In cases of progression or
recurrence, RT was delivered immediately. For those in the later trial, HIT-SKK92, three
cycles of methotrexate based chemotherapy were given after surgery. If recurrence or
progression occurred before 18 months, an experimental chemotherapeutic regimen was
recommended, while if these events occurred after 18 months, RT was administered.
Unfortunately, OS and PFS rates of 17.2% and 14.9%, respectively, were
extremely disappointing, confirming age younger than 3 as a negative prognostic
indicator. Still more troubling was the finding that of the 15 children that had received

no RT, only one survived. The administration of RT was a statistically significant
predictor of OS and PFS. The authors concluded that the omission of RT jeopardized
survival, even if intensive chemotherapy was administered in its stead. In their
discussion, they recommended that any delay in RT be limited to 6 months for children in
this age group. However, this study has been criticized on the grounds that, of the 15
patients that refused RT, 14 had early disease progression, suggesting that the no RT
group may have been sicker, on average, than those that had received RT (43).
However, a recent Canadian retrospective study of pediatric sPNET patients came
to a conclusion similar to that of Timmermann, et al (44). This study collected
information on sPNET patients less than 19 years of age who had been treated at thirteen
centers throughout Canada. In total, sufficient data was obtained on 48 patients. For
these patients, four-year survival stood at approximately 37%. The study confirmed that
very young patients had a worse OS than their older counterparts. Most significantly, the
authors found that the use of RT and chemotherapy significantly improved OS. For those
receiving radiation, the 4-year survival stood at 48.2% compared to 8.3% for those who
had not received radiation; for those receiving chemotherapy, four-year survival was 43%
compared to 12.5% survival for those that had not received chemotherapy. The authors
concluded that radiation should remain an important component in any treatment strategy
for sPNETs.
The importance of radiation as a component of multi-modal treatment has once
again and most recently been challenged by the results of the Head Start (HS) I and II
trials (45). These prospective trials enrolled 43 children with a median age of 3.1 years.
It should be noted that a significant percentage of the children, 47%, were less than 36

months of age. All patients first underwent a maximally safe surgical resection. Patients
in HSI and those with localized disease in HSII then underwent five cycles of treatment
with vincristine, cisplatin, cyclophosphamide, and etoposide. Patients in HSII with
disseminated disease had methotrexate added to the above regimen. Assuming disease
stability, patients then received a single cycle of high-dose myeloablative chemotherapy
followed by autologous stem cell rescue. Five-year event free survival (EFS) and OS
were 39% and 49% respectively and compared favorably to historical controls, some of
which were mentioned above. Perhaps most importantly, 60% of those surviving were
alive without exposure to RT. Surprisingly, in this study, age was not a significant
prognostic factor, nor was extent of disease or degree of surgical resection.
However, it should be noted that these findings regarding prognostic factors were
atypical. The majority of studies have concluded that the region in which the sPNET
arises is predictive of outcome, although it has not always been clear whether specific
regions portend better or worse outcomes. For instance, historically, it was assumed that
lesions arising in the pineal region carried a worse prognosis than non-pineal tumors.
Early retrospective studies, examining a total of 18 children suffering from pineal
sPNETs, found that 17 had rapidly progressive disease and died within 2 years of
diagnosis (46). However, recent data supports an opposite conclusion. In a sub-analysis
of prospective CCG data on 25 children with pineal sPNETs, including 8 infants, Jakacki,
et al found a 3-year PFS and OS for children over 18 months of age of 61% and 73%,
respectively (47). These outcomes, when compared to non-pineal sPNETs in a similar
age cohort, are impressive and the improvement has been attributed to the increasingly
common use of multi-modal therapy to treat patients with sPNETs. Unfortunately, these

advances do not seem to translate into improved survival for children with pineal sPNETs
under 18 months.
As we’ve mentioned, age, whether with pineal or non-pineal lesions, has shown
itself to be a robust predictor of outcome. A POG study looking at children with pineal
sPNETs confirmed the COG findings (48). For patients less than 18 months, progressive
disease developed relatively rapidly and responded poorly to radiotherapeutic
interventions. The same trends hold true for younger patients with non-pineal lesions. In
the CCG study, for patients age 19 to 36 months, all eventually succumbed to progressive
disease. A French Society of Pediatric Oncology study looked specifically at infants
suffering from sPNETs (49). The French study examined data from 25 patients less than
5 years of age who were treated with chemotherapy alone and found a relatively dismal 2
and 5-year survival rate of 30% and 14%, respectively. One obvious caveat is that these
patients received chemotherapy exclusively, so it’s unclear whether, if salvage RT had
been used, it would’ve produced survival rates commensurate with the older children’s.
What needs to be clarified regarding age is whether the worse prognoses that are being
consistently found are a result of a difference in sPNET biology and behavior in this age
group or an artifact of ginger treatment standards, with sub-optimal dosing of
chemotherapy and radiotherapy given to avoid possible side effects. This dilemma has
yet to be resolved.
A further factor with possible prognostic implications is the question of extent of
resection. Oftentimes, sPNETs will arise in eloquent areas of the cerebral cortex, making
gross total resection extraordinarily difficult; pineal region sPNETs also pose significant
surgical challenges. A study using CCG data found that large pre-operative tumors were,

not unsurprisingly, more likely to be associated with post-operative volumes of 1.5 cm^2
or greater (50). Less than 1.5cm^2 of residual tumor was seen in approximately 52% of
patients examined. Most significant was the finding that post-operative volumes less
than 1.5cm^2 carried with it a post-operative survival at 4-years of approximately 40%,
whereas those with residual volumes greater than the 1.5 cut-off had a dismal 4-year
survival of approximately 14%. Older trials have tended to confirm this earlier finding
(51). By comparison, in the more recent German HIT trials, resections were performed
to the safest extent possible, with only 38% achieving gross total resection as assessed by
imaging. However, there was not statistically significant difference in survival between
those that had received sub-total versus gross-total surgeries. More recent data argues for
the relative prognostic insignificance of extent of resection. The Canadian retrospective
study previous mentioned as well as the Heat Start trials also examined the prognostic
significance of extent of resection. In the Canadian study, 45% of patients had gross-total
resections. They found there to be no significant relationship between extent of resection
and survival. The Head Start trial divided patients into four groups, depending upon the
extent of resection: biopsy, partial resection, sub-total resection, and gross-total resection.
Again, their analyses revealed no relationship between extent of resection and overall
survival. It can be convincingly argued that, as the ability of both chemotherapy and
radiation to obtain local control increases, the relative importance of the extent of
resection will tend to recede. This may be why we see, in the more recent studies, the
extent of resection no longer acting as a significant prognostic variable.
The presence or absence of metastatic disease may also be of prognostic
importance in sPNET patients. The CCG study already mentioned showed that, for those

patients with metastatic disease, the survival rate was nearly 0% (37). A retrospective,
multi-institutional study of 22 patients with sPNET, five of whom had disseminated
disease at the time of diagnosis, found that all five of those patients had died by 5 years
after diagnosis (51). From these data, it would appear that metastasis at diagnosis
negatively impacts outcome. One could argue that the cranio-spinal irradiation and
chemotherapeutic regimens used in these studies were insufficient to eradicate metastatic
foci. More interestingly, however, is the conclusion from the Head Start trials that
metastasis at diagnosis did not portend significantly worse outcomes. Again, these trials
used intensive, myeloablative chemotherapy regimens. This finding was confirmed in
the German HIT trials which, again, found no impact of disease dissemination at
diagnosis on later outcomes. The idea that these intensive regimens, chemotherapy in the
Head Start and CSI in the German regimen, might achieve better systemic control could
help to explain the relative unimportance of dissemination at diagnosis.
Finally, we would like to discuss the importance of radiation therapy in the
treatment of sPNETs and its significance as a prognostic factor. One of the critical, and
still unanswered questions, is the extent to which field size is important in achieving
durable remission and enhancing survival. Although cranio-spinal irradiation (CSI) has
become the standard of care, prospective data supporting its use is lacking. Earlier,
prospective studies where patients received either CSI, whole-brain, or simply involved
field therapy evidenced no clear relative benefit for any one option (52, 53). One of the
more comprehensive of these retrospective studies was completed by Dirks, et al in
which they compiled clinical data on 36 patients that had received multimodal treatment
for sPNETs, with a median age of diagnosis of 35 months (7). They found that there was

no statistically significant difference between those who did receive CSI and those who
simply received whole brain irradiation (p=0.24). This is in contrast to Paulino, et al who
reported on 25 patients with sPNETs, with a quite divergent age range (12 months-32
years) (54). They found that 5-year survival for those patients that had received CSI was
47%. This was dramatically different when compared to those that had received whole
brain or focal field RT only; for these patients, 5-year survival was 12% and 0%,
respectively. Similarly, the German HIT trial on patients older than 3 years of age found
CSI to be a crucial component of any successful sPNET treatment.
Questions of proper radiation dosing are also critical. Again, in the German HIT
trial, any major deviations from defined radiotherapeutic protocols resulting in a
significant survival decrement. Major deviations were defined as a primary site dose of
less than 54 Gy or a craniospinal dose of less than 35 Gy. For instance, local doses of at
least 54 Gy resulted in a 3 year PFS of 44.7%, while doses lower than this limit had a
PFS of only 10%. In looking at CSI, doses above 35 Gy resulted in a 5-year PFS of
49.3% compared to 0% for those receiving a dose below this threshold. Attempts have
been made to increase both CSI and primate site doses, most notably by Prados, et al at
UCSF (55). This prospective study, which included approximately 25 medulloblastomas
and 11 sPNETs, used hyperfractionation to increase doses to the primary site to 72 Gy
with a reduction in doses to the cranio-spinal axis down to approximately 30 Gy using
1Gy dose per fraction. Unfortunately, while local control was adequate, there were a
significant number of distant failures, indicating, as in the German HIT Trial, that
reduction in CSI dose can compromise long-term survival. Additionally, no further
benefit seems to have been achieved with increased local dosing. Strategies that are still

under exploration include the use of radiotherapy in conjunction with possible
radiosensitizing agents, namely carboplatin. Carboplatin is a platinum-based
chemotherapeutic agent introduced in the late 1980s with a much more favorable sideeffect profile when compared to Cisplatin. The idea is that the radiosensitization will
allow for reduced radiation dosages. Currently, COG 99701 is attempting to determine
whether the addition of carboplatin will enhance outcomes in patients with high-risk
medulloblastomas and sPNETs. Eventually, a phase III trial will begin with patients
randomized to receive either radiotherapy alone or radiotherapy with concurrent
carboplatin administration.

SUMMARY AND STATEMENT OF PURPOSE/AIMS:

Treatment for sPNETs requires a multi-modality approach that includes
chemotherapy, surgery, and radiotherapy (RT). Results of prospective and retrospective
studies with either intentional or unintentional deviations from standard radiotherapeutic
protocol demonstrate reduced survival in patients not receiving standard-dose CSI (36
Gy) (38, 56, 57). However, the Head Start trials, which examined a patient population
with a median age of 3.1 years, shows that treatment with high-dose chemotherapy alone
followed by stem cell rescue allows for a reduction or elimination of radiation without
adversely impacting overall survival (45). Current Children’s Oncology Group (COG)
Protocols classify sPNETs with high-risk medulloblastomas and thus call for treatment
that involves standard dose CSI.

In light of this uncertainty over the role of radiation, we performed a historical
cohort study to evaluate its utility in pediatric patients with sPNET treated at the
University of California, San Francisco (UCSF). We sought to determine whether there
was any evidence supporting delay, elimination, or reduction in field size or dose of
radiation.

MATERIALS AND METHODS
Nineteen consecutive children <18 years old with non-pineal sPNETs diagnosed
between December 1992 and December 2006 who received surgery at UCSF were
identified. Four patients with inadequate follow-up (FU) were excluded, leaving 15
evaluable patients (Table 1). Inadequate FU was defined as lack of any information
following surgery at UCSF, resulting from patients who did not reside locally and were
lost-to-follow-up soon after their tumor resection, despite our concerted efforts to locate
them. The median age at diagnosis was 3.1 years (range 0.2–12) and 33% were males.
All patients were staged using spine MRIs with and without gadolinium and CSF
cytology. Initial therapy consisted of surgery and chemotherapy (CT) in all patients and
RT in 5 patients. Surgical intent was to achieve gross total resection (GTR) whenever
possible. The extent of surgery was determined by reviews of the operative reports and
postoperative radiologic studies. The most common chemotherapeutic regimen consisted
of cisplatin, etoposide, cyclophosphamide, and vincristine; 2 patients received high-dose
CT with autologous stem cell rescue. RT regimens consisted predominantly of external
beam radiotherapy (EBRT) to the tumor bed with the addition of CSI in certain patients
delivered at the discretion of the treating physician. The use and timing of RT was

determined by the treating Radiation Oncologist and largely based on the patient’s
functional status, age, and physician preference. The choice between CSI and focal RT
was made at the discretion of the Radiation Oncologist and was heavily influenced by the
age of the patient, as those younger than three years of age were more likely to receive
focal RT than CSI.
All statistical analyses were performed using Statistica V 6.0 and StatXact-8.
Kaplan-Meier methods were used to calculate overall survival (OS). Progression Free
Survival (PFS) was calculated by defining the date of progression as the first mention of
progression in imaging reports. All P values were determined using the exact log rank
test and are two-tailed. Significance was defined as a P-value < 0.05. OS was defined as
the time period between resection and death or date last known alive.

RESULTS
Patient characteristics are summarized in Table 1. The median follow-up from
resection for all patients was 31 months (range, 0.5-165) and for surviving patients was
49 months (range, 10-165). All patients presented with non-pineal, supra-tentorial
lesions. Only 2 of 15 patients presented with disseminated disease (M+) at diagnosis. In
keeping with the observed sPNET demographics, 7 of the 15 patients were less than 3
years of age.
As part of their initial therapy, 5 patients received upfront RT, with total doses
ranging from 50.4 to 72 Gy (Table 2A). Of the 5 patients with upfront EBRT, 4 received
CSI with doses ranging from 23.4 to 36 Gy. Notably, all of the patients who received

upfront RT were alive without evidence of disease at a median follow-up of 50 months
(range, 25-165).
Of the 10 patients who did not have up-front RT, 5 received it as salvage therapy
at the time of progression. Of those 5, all experienced local failure either as the first or
sole site of recurrence (Table 2B). Three of these salvage patients received EBRT with
doses ranging from 54-57.6 Gy. In addition, one patient received brachytherapy using
permanent Iodine-125 seeds and one patient received both EBRT and Iodine-125 seeds.
Three of the patients who received salvage RT were alive without evidence of disease at
last follow-up, 33, 102, and 111 months after diagnosis. Of the 5 patients who did not
receive any RT either up-front or as salvage, 2 were alive at last follow-up (Table 2C).
However, follow-up for these patients was comparatively short at 10 and 28 months. Of
the 3 patients that died of disease, 1 had local and 1 had disseminated failure at the time
of progression; an additional patient died 14 days after initial resection. Overall, only 5
of the 10 patients who did not receive up-front RT were alive at last follow-up. There
was a statistically significant difference in overall survival between the group of patients
that received up-front RT and the group that did not (P=0.048; Fig. 1).
Regarding Progression Free Survival (PFS), we found that for those patients who
had received up-front radiation, none had progressed as of last follow-up. This is in
sharp contrast to the group that did not receive up-front RT in which 8 out of 10 patients
progressed, with a median time to progression of 6.5 months (range, 0-26).
In examining the RT fields utilized in the 10 patients who received RT (5 at
diagnosis and 5 at progression), 5 had CSI and 5 had focal field only. Of the 5 patients
who received CSI, none of the 4 who received radiation as part of up-front therapy

progressed; of note, 2 of these patients received standard dose of 36 Gy whereas 2
patients received reduced dose of 23.4 Gy. The single patient who received CSI (23.4
Gy) as salvage therapy died of his disease. Of the 5 patients whose RT consisted of focal
field only, all were under 3 years of age and 4 were alive without evidence of disease at
follow-up times ranging from 33-111 months after diagnosis. One patient died of her
disease 31 months after diagnosis.
Children younger than 3 years with sPNETs have a particularly poor prognosis.
Our cohort included 7 patients less than 3 years of age at diagnosis; five of these young
children were alive and NED at last FU (range 3-111 months after diagnosis). Four of
these 5 surviving infants received RT as part of their treatment, all consisting of focal
field only (1 as part of initial therapy and 3 as salvage).
Finally, within our cohort, 8 of 15 patients had gross-total resections. For those
receiving GTRs, one patient died at 31 months, with the remainder still alive and NED at
median follow-up of 48 months (range, 25-165 months). Of the 7 patients receiving
incomplete resections, 4 died at 0.5, 3, 5, and 21 months; three remain alive at last
follow-up of 10, 50, and 111 months. After stratifying for up-front RT versus salvage or
no RT, we found a trend towards an improvement in overall-survival for those patients
that had received GTRs (P=0.10).

DISCUSSION
Traditionally, the treatment of sPNETs has involved surgery coupled with various
chemotherapy and radiation regimens. Because of its significant morbidity, especially
when administered to the entire cranio-spinal axis, attempts have been made to eliminate,

delay, or limit radiotherapy. Unfortunately, such trials have shown decidedly mixed
results.
Our study attempted to ascertain the importance of radiotherapy in the treatment
of children diagnosed with sPNETs. Despite the relatively few patients in our
retrospective analysis, we feel that several points can be made. First, up-front
radiotherapy does appear to offer a statistically significant improvement in OS in this
study. This is consistent with the findings of Timmermann, et al. in their recent
prospective study (38). However, our conclusion must be tempered by the obvious
presence of a significant confounding variable. Among patients who did not receive upfront RT, 3 of the deaths occurred very soon after resection, with the decision not to give
RT possibly related to a compromised clinical condition. As such, it is possible that these
patients were significantly sicker on average than the patients in the up-front group.
Indeed, when we eliminate the child who died soonest after resection (2 weeks), the
resultant P value is 0.10, above the value of statistical significance. An additional
potential concern is that, of the 7 children younger than 3 years of age, 6 were in the
group that did not receive up-front RT. Since children under 3 have historically had a
worse prognosis, this could represent a significant confounding variable. However, 4 of
these 6 children remain alive at last follow-up and therefore we view confounding
findings secondary to age as likely negligible in this study. The same caveats clearly
apply to our data on progression. While our results for PFS suggest a benefit for up-front
RT versus delayed RT, radiographic imaging was not systematically and uniformly
acquired for all patients to assess progression, diminishing the strength of these findings.

We must also mention that re-grouping these patients by whether they received
RT at all instead of the timing of RT is equally informative. With this grouping we find
that 8 of 10 children that had RT are NED at the time of last follow-up compared with 2
of 5 children that never received RT. Either grouping is clinically instructive, but both
share the same aforementioned limitations
Despite a small number of patients, patterns of failures are instructive. Eight
patients progressed, all among children who did not receive radiation up-front. Five of
these 8 failures were M0 at initial diagnosis and presented with local failure as the sole or
first site of recurrence. This is consistent with results from the German HIT Trials where
approximately 71% of patients had localized treatment failure. Given these data, one
could hypothesize the existence of a subset of patients with tumors that have a decreased
potential for metastatic spread. For these patients, focal irradiation following reduceddose CSI or perhaps even without CSI in selected cases may be a feasible strategy.
Alternately, since all patients received chemotherapy, one might argue that, in a subset of
these patients, the regimen was sufficient to eliminate micrometases but was inadequate
for primary tumor control.
In instances where field size was limited, our experience is encouraging as 3 of 4
M0 patients who received only focal RT are, as of last follow-up, without evidence of
disease. However, given the small sample size, it is impossible to make explicit
recommendations regarding which patients might benefit from a reduction in field sizes.
However, we do believe that these data, at the very least, provide a strong rationale for
the initiation of a larger randomized controlled trial designed to determine which patients
might benefit from either a reduction in dose or complete elimination of CSI.

Finally, it does appear that, even after controlling for radiotherapy timing, there is a trend
towards improved OS with more extensive resections. This is consistent with previously
published results, but in contrast to a recent Canadian retrospective analysis that suggests
that OS does not correlate with extent of resection (7,35,50). We believe a larger cohort
of patients might help to determine the exact nature of the relationship between degree of
resection and survival.
Overall, our data are consistent with the goal of maximal resection of these
tumors in children and argues that RT plays a very important role in adjuvant treatment.
Ultimately, a prospective trial considering survival and neuropsychological sequelae and
comparing various chemotherapy-radiation regimens may be required to finally establish
a standard of care specific to patients with this deadly tumor.
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Table 1: Patient Characteristics and Treatment Details

Patient characteristics
Median age (range)
Sex M:F

Number of Patients
36 months (2-144)
5:10

CNS disseminations: M0

3

M+

2

Radiation therapy: Up-front

5

At time of recurrence

5

None

5

Extent of resection: Gross total resection

8

Incomplete resection

7

Table 2A: Patients receiving radiation as component of initial treatment

Pt#

Extent Primary
CSI
of
Tumor
Age Stage
Dose
Resect Dose
(Gy)
ion
(Gy)

1

34

M0

GTR

50.4

0

2

48

M0

GTR

72.0

36

3

60

M0

GTR

55.8

23.4

4

60

M0

GTR

55.8

36

5

144

M0

STR

59.4

23.4

Chemo
Mafosphamide
, Cisplatin,
Cyclophos,
VCR,
Etoposide
Procarbazine,
CCNU, VCR
CCNU, VCR,
Cisplatin
Carboplatin,
VCR,

Cyclophos
CCNU, VCR,
Cisplatin

Pattern of
OS
Failure (months)

Status

No failure

48

NED

No failure

165

NED

No failure

80

NED

No failure

25

NED

No failure

50

NED

Abbreviations: GTR: gross total resection; STR: subtotal resection; CSI:
cranio-spinal irradiation; FU: follow-up; NED: no evidence of disease;
VCR: Vincristine; MTX: Methotrexate, TMZ: Temozolomide.

Table 2B: Patients receiving radiation as component of salvage treatment

Pt#

6

§

Age

Extent
Tumor CSI
of
Chemotherapy:
Stage
Dose Dose
Agents used for
Resecti
(Gy) (Gy)
each patient
on

2

M0

GTR

57.6

7

14

M0

GTR

54.0

8

21

M+

STR

90.0*

9

24

M0

GTR

36.0 +
80*

10

72

M0

STR

54.0

Pattern of
Failure

PFS

OS Status

Cyclophos,
Local followed by
DOD
0
7 31
Etoposide, VCR,
CNS
Cisplatin, MTX
dissemination
Cyclophos,
Etoposide, VCR,
0
Local
33 NED
Cisplatin, TMZ,
9
Lenalidomide,
Accutane, CCNU
MTX, Cyclophos,
0
Local
26 111 NED
VCR, Cisplatin,
Etoposide
Cyclophos, VCR,
0
Local
7 102 NED
Etoposide
Cyclophos,
Etoposide, VCR,
23.4 Cisplatin, TMZ,
Local
6 21 DOD
Procarbazine,
CCNU

*Brachytherapy using I-125 permanent seeds
§
Patient received stem cell rescue
Abbreviations: GTR: gross total resection; STR: subtotal resection; CSI:
cranio-spinal irradiation; FU: follow-up; NED: no evidence of disease;
DOD: dead of disease; VCR: Vincristine; MTX: Methotrexate, TMZ:
Temozolomide, Cyclophos: Cyclophosphamide, PFS: Progression Free
Survival, OS: Overall Survival.

Table 2C: Patients who never received radiation therapy

Patient

11

Age

12

Primary
Extent of Tumor
Stage
Resection Dose
(Gy)
M0

STR

0

CSI
Dose
(Gy)

0

12

24

M0

GTR

0

0

13

36

M0

STR

0

0

14§

36

M0

STR

0

0

15

120

M+

STR

0

0

Chemo

Pattern of
Failure

Cisplatin,
Etoposide,
Cyclophos

Concurrent
local and
CNS
disseminati
on

Progressio
Disease
n Free Overall
Status at
Surival Surv.
Last FU
(months)
3

Cisplatin,
No
Etoposide,
No failure
progression
Cyclophos,
VCR
Carboplatin,
Local
1
VCR,
Cyclophos
MTX, VCR,
Etoposide,
Cisplatin,
No
No failure
Cyclophos,
Progression
Thiotepa,
Carboplatin
Ifosphamide
0
Carboplat NA*
Etoposid

Abbreviations: GTR: gross total resection; STR: subtotal resection; CSI:
cranio-spinal irradiation; FU: follow-up; NED: No evidence of disease;
DOD: dead of disease; VCR: Vincristine; MTX: Methotrexate, TMZ:
Temozolomide, Cyclophos: Cyclophosphamide.
* Patient died 14 days after resection, before complete disease status
evaluation could be conducted.
§
Patient received stem cell rescue

4

DOD

28

NED

5

DOD

10

NED

0.5

DOD

FIGURE LEGENDS
Figure 1: Overall survival according to whether patients did or did not receive radiation
therapy as a component of initial treatment.

